UniQure announced plans Wednesday to seek FDA approval for its experimental gene therapy targeting Huntington's disease, a rare hereditary condition that gradually destroys nerve cells in the brain. The announcement sent shares soaring 70% as investors reacted to what amounts to a stunning regulatory reversal from just months earlier.

Market Context

The move comes amid broader volatility in the biotech sector, where regulatory decisions have become increasingly unpredictable under shifting FDA leadership. UniQure's surge added momentum to an already-active trading session for gene therapy names, with traders pointing to the company's announcement as a potential template for other rare disease developers facing similar agency pushback.

Analysis

The FDA communicated in a recent meeting that a three-year analysis from UniQure's Phase 1/2 study would support accelerated approval of the gene therapy. This marks a dramatic pivot from March, when the regulator told UniQure its clinical trial data wouldn't support an application and publicly criticized the company's evidence. Former FDA Commissioner Marty Makary had described the treatment in a February interview without naming it, saying the agency was pressured to approve it even though it showed "no benefit." Makary left the agency in May along with other senior leaders including former Center for Biologics Evaluation and Research director Vinay Prasad.

The gene therapy is administered directly into the brain through an hours-long surgical procedure. UniQure has argued it would be unethical to require patients to undergo a sham procedure as part of a placebo-controlled trial. Instead, the company compared disease progression in treated patients against typical Huntington's progression using an external database—an approach that initially drew FDA skepticism.

Traders noted that UniQure isn't alone in seeing fortunes reverse following leadership changes at the agency. Replimune recently announced it would seek approval of its experimental melanoma drug for a third time, suggesting a broader shift in how the FDA evaluates novel therapies under new management.

Key Numbers

- 70% surge in UniQure shares on Wednesday following the announcement

- 75% slowdown in disease progression observed in Phase 1/2 trial using external control comparison

- Q3 2026 targeted submission date for the marketing application

- Three-year data analysis from Phase 1/2 study cited as basis for accelerated approval pathway

What to Watch

UniQure plans to submit its application in the third quarter of this year. The FDA wants to align on a confirmatory study design before submission, including comparison against standard of care rather than a sham procedure. Investors will monitor whether the company can finalize those plans on schedule and how other rare disease drugmakers respond to the regulatory shift.

The stock's 70% jump reflects significant optimism priced into shares, meaning any delays or complications in the approval process could trigger sharp reversals. Traders should also watch for unusual options activity as market participants position around binary catalysts tied to FDA decision dates.